project . 2020 - 2022 . On going

SCORE

Swift COronavirus therapeutics REsponse
Open Access mandate for Publications European Commission
  • Funder: European CommissionProject code: 101003627 Call for proposal: H2020-SC1-PHE-CORONAVIRUS-2020
  • Funded under: H2020 | RIA Overall Budget: 2,627,550 EURFunder Contribution: 2,576,060 EUR
  • Status: On going
  • Start Date
    01 Apr 2020
    End Date
    31 Mar 2022
  • Detailed project information (CORDIS)
  • Open Access mandate
    Research Data: No
Description
Coronavirus 2019-nCoV has become a worldwide public health emergency, and the lack of vaccines and drugs to immediately address this outbreak is painfully clear. Even if the epidemic can be stopped, the virus may return in the same or a modified form. More than vaccines and therapeutic antibodies, antiviral drugs can target highly conserved viral functions and have the broad-spectrum activity that is critical to combat current and future outbreaks. Since the 2003 SARS outbreak, as leading academic coronavirus researchers, we have collaborated to understand and inhibit coronavirus replication. We defined viral key functions, developed tools for inhibitor screenin...
Description
Coronavirus 2019-nCoV has become a worldwide public health emergency, and the lack of vaccines and drugs to immediately address this outbreak is painfully clear. Even if the epidemic can be stopped, the virus may return in the same or a modified form. More than vaccines and therapeutic antibodies, antiviral drugs can target highly conserved viral functions and have the broad-spectrum activity that is critical to combat current and future outbreaks. Since the 2003 SARS outbreak, as leading academic coronavirus researchers, we have collaborated to understand and inhibit coronavirus replication. We defined viral key functions, developed tools for inhibitor screenin...
Any information missing or wrong?Report an Issue